Company Filing History:
4 out of 151 
2 out of 2,483 
2 out of 1,152 
Years Active: 2013-2023
Title: Innovations of Markus Fries in Blood Coagulation
Introduction
Markus Fries is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of blood coagulation through his innovative research and development. With a total of five patents to his name, his work focuses on enhancing our understanding and treatment of blood coagulation disorders.
Latest Patents
One of his latest patents involves TFPI inhibitors and methods of use. This invention provides peptides that bind to Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides and their compositions. The peptides may be utilized to inhibit TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation, treat blood coagulation disorders, purify TFPI, and identify TFPI-binding compounds. This innovative approach has the potential to significantly impact the treatment of various coagulation disorders.
Career Highlights
Throughout his career, Markus Fries has worked with prominent companies in the healthcare sector, including Baxalta GmbH and Baxter International Inc. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in medical science.
Collaborations
Markus has collaborated with esteemed colleagues such as Michael Dockal and Rudolf Hartmann. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Markus Fries is a distinguished inventor whose work in blood coagulation has led to significant advancements in medical treatments. His innovative patents and collaborations highlight his commitment to improving healthcare outcomes.